title: Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling.
abstract: Psoriasis is recognized as the most common T cell-mediated inflammatory disease in humans. Genetic linkage to as many as six distinct disease loci has been established but the molecular etiology and genetics remain unknown. To begin to identify psoriasis disease-related genes and construct in vivo pathways of the inflammatory process, a genome-wide expression screen of multiple psoriasis patients was undertaken. A comprehensive list of 159 genes that define psoriasis in molecular terms was generated; numerous genes in this set mapped to six different disease-associated loci. To further interpret the functional role of this gene set in the disease process, a longitudinal pharmacogenomic study was initiated to understand how expression levels of these transcripts are altered following patient treatment with therapeutic agents that antagonize calcineurin or NF-KB pathways. Transcript levels for a subset of these 159 genes changed significantly in those patients who responded to therapy and many of the changes preceded clinical improvement. The disease-related gene map provides new insights into the pathogenesis of psoriasis, wound healing and cellular-immune reactions occurring in human skin as well as other T cell-mediated autoimmune diseases. In addition, it provides a set of candidate genes that may serve as novel therapeutic intervention points as well as surrogate and predictive markers of treatment outcome.
authors.affiliation: Division of Molecular Medicine, Genetics Institute/Wyeth-Ayerst Research, Cambridge, MA, USA.
authors.forename: J L
authors.initials: JL
authors.lastname: Oestreicher
authors.forename: I B
authors.initials: IB
authors.lastname: Walters
authors.forename: T
authors.initials: T
authors.lastname: Kikuchi
authors.forename: P
authors.initials: P
authors.lastname: Gilleaudeau
authors.forename: J
authors.initials: J
authors.lastname: Surette
authors.forename: U
authors.initials: U
authors.lastname: Schwertschlag
authors.forename: A J
authors.initials: AJ
authors.lastname: Dorner
authors.forename: J G
authors.initials: JG
authors.lastname: Krueger
authors.forename: W L
authors.initials: WL
authors.lastname: Trepicchio
mesh_terms: D000328:Adult; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods* / Q000706:statistics & numerical data; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017370:Interleukin-11 / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods / Q000706:statistics & numerical data; D010597:Pharmacogenetics / Q000379:methods* / Q000706:statistics & numerical data; D011565:Psoriasis / Q000145:classification* / Q000188:drug therapy / Q000235:genetics*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D017370:Interleukin-11; D012333:RNA, Messenger; D011994:Recombinant Proteins; D016572:Cyclosporine; C105308:oprelvekin